Early‐phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease

Author:

Aye William W. T.12,Stark Megan R.1,Horne Kyla‐Louise12,Livingston Leslie1,Grenfell Sophie1,Myall Daniel J.1,Pitcher Toni L.12,Almuqbel Mustafa M.13,Keenan Ross J.13,Meissner Wassilios G.145,Dalrymple‐Alford John C.16,Anderson Tim J.127,Heron Campbell Le1267,Melzer Tracy R.1236ORCID

Affiliation:

1. New Zealand Brain Research Institute Christchurch New Zealand

2. Department of Medicine University of Otago Christchurch New Zealand

3. Radiology Holding Company New Zealand Christchurch New Zealand

4. CHU Bordeaux, Service de Neurologie des Maladies Neurodégénératives IMNc, NS‐Park/FCRIN Network Bordeaux France

5. Univ. Bordeaux, CNRS, IMN Bordeaux France

6. School of Psychology, Speech and Hearing, University of Canterbury, Psychology Speech and Hearing Arts Road, Ilam Christchurch New Zealand

7. Department of Neurology Canterbury District Health Board Christchurch New Zealand

Abstract

AbstractINTRODUCTIONRecent work suggests that amyloid beta (Aβ) positron emission tomography (PET) tracer uptake shortly after injection (“early phase”) reflects brain metabolism and perfusion. We assessed this modality in a predominantly amyloid‐negative neurodegenerative condition, Parkinson's disease (PD), and hypothesized that early‐phase 18F‐florbetaben (eFBB) uptake would reproduce characteristic hypometabolism and hypoperfusion patterns associated with cognitive decline in PD.METHODSOne hundred fifteen PD patients across the spectrum of cognitive impairment underwent dual‐phase Aβ PET, structural and arterial spin labeling (ASL) magnetic resonance imaging (MRI), and neuropsychological assessments. Multiple linear regression models compared eFBB uptake to cognitive performance and ASL MRI perfusion.RESULTSReduced eFBB uptake was associated with cognitive performance in brain regions previously linked to hypometabolism‐associated cognitive decline in PD, independent of amyloid status. Furthermore, eFBB uptake correlated with cerebral perfusion across widespread regions.DISCUSSIONEFBB uptake is a potential surrogate measure for cerebral perfusion/metabolism. A dual‐phase PET imaging approach may serve as a clinical tool for assessing cognitive impairment.Highlights Images taken at amyloid beta (Aβ) positron emission tomography tracer injection may reflect brain perfusion and metabolism. Parkinson's disease (PD) is a predominantly amyloid‐negative condition. Early‐phase florbetaben (eFBB) in PD was associated with cognitive performance. eFBB uptake reflects hypometabolism‐related cognitive decline in PD. eFBB correlated with arterial spin labeling magnetic resonance imaging measured cerebral perfusion. eFBB distinguished dementia from normal cognition and mild cognitive impairment. Findings were independent of late‐phase Aβ burden. Thus, eFBB may serve as a surrogate measure for brain metabolism/perfusion.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3